Sage Therapeutics stockholders approve ESPP share increase and bylaw amendments at annual meeting

Sage Therapeutics, Inc.

Stockholders approved 500,000-share increase to the 2014 ESPP, effective immediately.
Bylaws amended to add universal proxy rules, emergency provisions, and technical updates.
Directors elected: Michael F. Cola, Barry E. Greene, Jeffrey M. Jonas, M.D., Jessica J. Federer as Class III.
Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2023.
Advisory vote on executive compensation passed with 39,995,146 for (77.5%) vs 11,173,607 against.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sage Therapeutics, Inc.: Amended and restated bylaws to eliminate requirement for stockholder list at meetings, address technical failures in remote meetings, add emergency bylaws, and revise director nomination procedures under universal proxy rules (effective 2023-06-15).

Change: bylaw amendment
Effective: 2023-06-15

Exact text from the filing

On June 15, 2023, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, as amended (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sage Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation.

Proposal: say on pay
Outcome: passed

Exact text from the filing

A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sage Therapeutics, Inc. shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-12-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-31

Exact text from the filing

The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023, was ratified.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sage Therapeutics, Inc. shareholders approved Amendment to 2014 ESPP to increase authorized shares by 500,000.

Proposal: equity plan
Outcome: passed

Exact text from the filing

The amendment to the 2014 ESPP to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 500,000 shares was approved.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sage Therapeutics, Inc. shareholders approved Election of four Class III directors.

Proposal: director election
Outcome: passed

Exact text from the filing

The following nominees were elected to the Company’s Board as Class III directors for terms expiring at the 2026 annual meeting of stockholders.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-168975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.